Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carfilzomib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01729104
What this trial is testing

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT01246063
What this trial is testing

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 40
Testing effectiveness (Phase 2)WithdrawnNCT02628704
What this trial is testing

Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc
Testing effectiveness (Phase 2)Active Not RecruitingNCT04822337
What this trial is testing

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wake Forest University Health Sciences 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03314636
What this trial is testing

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Who this might be right for
Myeloma
Oslo University Hospital 53
Testing effectiveness (Phase 2)Study completedNCT02937571
What this trial is testing

High Dose Carfilzomib for Newly Diagnosed Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 29
Early research (Phase 1)Looking for participantsNCT03909412
What this trial is testing

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT02415413
What this trial is testing

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
PETHEMA Foundation 90
Not applicableStudy completedNCT06568952
What this trial is testing

Right Ventricular Function in Patients Taking Carfilzomib

Who this might be right for
Pulmonary Hypertension
Central Hospital, Nancy, France 36
Early research (Phase 1)Study completedNCT01301807
What this trial is testing

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Non-Secretory Plasma Cell MyelomaPlasmacytosisRecurrent Plasma Cell Myeloma+1 more
M.D. Anderson Cancer Center 63
Testing effectiveness (Phase 2)Study completedNCT01351623
What this trial is testing

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 44
Testing effectiveness (Phase 2)Study completedNCT01572480
What this trial is testing

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 55
Large-scale testing (Phase 3)Study completedNCT01080391
What this trial is testing

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Who this might be right for
Relapsed Multiple Myeloma
Amgen 792
Testing effectiveness (Phase 2)Active Not RecruitingNCT01297764
What this trial is testing

Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 17
Early research (Phase 1)Study completedNCT02335983
What this trial is testing

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 107
Testing effectiveness (Phase 2)Ended earlyNCT02042950
What this trial is testing

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Early research (Phase 1)Ended earlyNCT03031730
What this trial is testing

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Who this might be right for
PlasmacytomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT01372540
What this trial is testing

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
M.D. Anderson Cancer Center 76
Testing effectiveness (Phase 2)Looking for participantsNCT06140966
What this trial is testing

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple MyelomaPrimary Plasma Cell LeukemiaExtramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 54
Testing effectiveness (Phase 2)Study completedNCT01496118
What this trial is testing

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 80
Next Page